A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Official Title

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)


This study will assess the safety and efficacy of VS-6766 monotherapy and in combination with Defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Trial Description

Primary Outcome:

  • Part A: Determine optimal regimen of VS-6766 monotherapy or in combination with defactinib
  • Part B: To determine the efficacy of the optimal regimen identified from Part A
Secondary Outcome:
  • Overall Response Rate as assessed by Investigator
  • Duration of Response (DOR)
  • Disease Control Rate (DCR)
  • Progression Free Survival (PFS)
  • Overall Survival (OS)
This is a multicentre, randomized, open-label Phase 2 study designed to evaluate safety and tolerability and preliminary efficacy of VS-6766 versus VS-6766 in combination with defactinib in subjects with molecularly profiled recurrent LGSOC.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society